Featured Firms
Presented by BigVoodoo
Can a generic drug maker be held liable for failure-to-warn claims because its version of a popular drug gained FDA recognition as the industry standard? Not according to a ruling last week by a federal judge in Atlanta, who ruled that labeling claims against Mylan over its version of an anti-seizure drug were preempted under the Supreme Court's Pliva v. Mensing decision.
January 10, 2012 at 12:00 AM
1 minute read
Presented by BigVoodoo
Join General Counsel and Senior Legal Leaders at the Premier Forum Designed For and by General Counsel from Fortune 1000 Companies
Join General Counsel and Senior Legal Leaders at the Premier Forum Designed For and by General Counsel from Fortune 1000 Companies
Honoring outstanding legal achievements focused at the national level, largely around Big Law and in-house departments.
Truly exceptional Bergen County New Jersey Law Firm is growing and seeks strong plaintiff's personal injury Attorney with 5-7 years plaintif...
Shipman is seeking an associate to join our Labor & Employment practice in our Hartford, New Haven, or Stamford office. Candidates shou...
Evergreen Trading is a media investment firm headquartered in NYC. We help brands achieve their goals by leveraging their unwanted assets to...
MELICK & PORTER, LLP PROMOTES CONNECTICUT PARTNERS HOLLY ROGERS, STEVEN BANKS, and ALEXANDER AHRENS